Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2004-000558-22Phase 3Completed
Phase 3, single-arm trial of peginterferon alfa-2b and ribavirin in hepatitis C virus infection, sponsored by Merck & Co. Primary endpoints: Safety and Efficacy. Started Sep 2005; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2004-000558-22.